98435-76-8

Basic information

• Product Name: 1-ethyl-L-Proline
• Synonyms: 1-ethyl-L-Proline
• CAS NO: 98435-76-8
• Molecular Formula: C₇H₁₃NO₂
• Molecular Weight: 143.18362
• Mol File: 98435-76-8.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-ethyl-L-Proline(CAS DataBase Reference)
• NIST Chemistry Reference: 1-ethyl-L-Proline(98435-76-8)
• EPA Substance Registry System: 1-ethyl-L-Proline(98435-76-8)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 98435-76-8(Hazardous Substances Data)

Usage

Chemical compound

1-Ethyl-L-proline is a chemical compound derived from the natural amino acid L-proline by the addition of an ethyl group.

Proline family

It belongs to the proline family of amino acids, which are essential building blocks of proteins.

Unique properties

The addition of an ethyl group to L-proline gives 1-ethyl-L-proline unique properties that make it suitable for various applications in pharmaceutical and chemical industries.

Chiral building block

1-Ethyl-L-proline is commonly used as a chiral building block in the synthesis of pharmaceutical drugs.

Molecular scaffold

It serves as a molecular scaffold for the development of new chemical entities.

Chiral nature

The chiral nature of 1-ethyl-L-proline makes it a valuable tool in drug discovery and development.

Structural features

The unique structural features of 1-ethyl-L-proline contribute to its utility in various applications.

Organic synthesis

1-Ethyl-L-proline has found applications in organic synthesis.

Dietary supplements

It is also used as a component in the preparation of certain dietary supplements.

Upstream product

• 64-17-5 ethanol 
• 609-36-9 rac-Pro-OH 
• 107599-40-6 N-ethyl-L-proline methyl ester 
• 16652-71-4 benzyl (2S)-2-pyrrolidinecarboxylate hydrochloride 
• 54288-59-4 diethyl 2-bromo-2-(3-bromopropyl)malonate 
• 101738-88-9 1-ethyl-pyrrolidine-2,2-dicarboxylic acid diethyl ester 
• 147-85-3 L-proline 
• 74-96-4 ethyl bromide 
• 41324-66-7 H-Pro-OBzl 

Downstream Products

• 354563-99-8 (4-Benzylpiperidin-1-yl)-((2S)-1-ethylpyrrolidin-2-yl)-methanone hydrochloride 
• 1105044-37-8 (2S,2'S)-[(1S,2S)-1,2-diphenylethane-1,2-diyl] bis[1-ethylpyrrolidine-2-carboxylate] 
• 1247709-13-2 (5R,8S)-7-((2S)-2-(((2S)-2-cyclohexyl-2-((((2S)-1-ethylpyrrolidin-2-yl)carbonyl)amino)acetyl)amino)-3:3-dimethylbutanoyl)-10,10-dimethyl-N-((1R,2S)-1-(((1-propylcyclopropyl)sulfonyl)carbamoyl)-2-ethylcyclopropyl)-7-azadispiro[3.0.4.1]decane-8-carboxamide 
• 1412974-79-8 (1aRS,7bSR)-5-{2-[((S)-1-ethylpyrrolidin-2-yl)carbonylaminomethyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid 
• 3433-34-9 1-ethyl-2-hydroxymethylpyrrolidine 
• 938-54-5 N-ethyl ethyl prolinate 

Relevant articles and documents

EPHA4 CYCLIC PEPTIDE ANTAGONISTS AND METHODS OF USE THEREOF

Disclosed herein are compounds and methods of use thereof for the modulation of EphA4 receptor activity. In an aspect, is provided a method of treating or preventing a disease or disorder mediated by EphA4, comprising administering to a subject in need thereof a therapeutically effective amount of a compound as described herein, including certain embodiments, or the structural Formula (I), (l-A), (II), (III), (IV), (IV-1), (V), (Vl-A), (Vl-B), (VII-1), (VII-2), (VIII-1), or (VIII-2), or an enantiomer, a mixture of enantiomers, a mixture of two or more diastereomers, or an isotopic variant thereof; or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

2-PYRROLIDINE PHENYLHYDRAZIDES ANTIBACTERIAL AGENTS

2-Pyrrolidine phenylhydrazides antibacterial agents The present invention relates to 2-pyrrolidine phenylhydrazide compounds of formula (I), which are selective antibacterials specifically agalnstAcineto barter baumannii.The invention also relates to their therapeutic use as antibacterials, to a process for their preparation and to pharmaceutical compositions containing them.

Modulating hydrogen-bond basicity within the context of protein-ligand binding: A case study with thrombin inhibitors that?reveals a dominating role for desolvation

Understanding subtle aspects of hydrogen bonding is a challenging but crucial task to improve our ability to design ligands with high affinity for protein hosts. To gain a deeper understanding of these aspects, we investigated a series of thrombin inhibitors in which the basicity of the ligand's group that accepts an H-bond from Gly216 was modulated via bioisosterism; e.g., a C=O acceptor was made electron deficient or rich via bioisosteric replacements of the adjacent moiety. Although the ligand's binding affinity was anticipated to improve when the H-bond basicity is increased (due to stronger H-bonding with the protein), we herein present data that unexpectedly revealed an opposite trend. This trend was attributed to a dominating role played by desolvation in determining the relative binding affinity. For example, a decrease in the H-bond basicity reduces the desolvation penalty and, as experimentally observed, improves the binding affinity, given that the reduction in the desolvation penalty dominates the change in the net contribution of the ligand's interactions with the protein. The current study, therefore, reveals that desolvation can be a major underlying cause for the apparently counterintuitive structure-activity relationship (SAR) outcomes, and indicates that understanding this factor can improve our ability to predict binding affinity and to design more potent ligands.